Assay In Which A Label Present Is An Enzyme Substrate Or Substrate Analogue Patents (Class 435/7.72)
  • Patent number: 10401368
    Abstract: Disclosed herein are antibodies having binding specificity to the amino acid sequences Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) and Thr Val Glu Val Asp (SEQ ID NO:14), and methods of detecting cell death in a sample, comprising contacting the sample with a first antibody specific for a C-terminal amino acid sequence Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) or Thr Val Glu Val Asp (SEQ ID NO:14) of a CK18 protein fragment having a C-terminal amino acid sequence of Val Glu Val Asp (SEQ ID NO:2) and a second antibody that specifically binds an epitope that is present in both full-length CK18 and the CK18 protein fragment, and that does not overlap with SEQ ID NO:1 or SEQ ID NO:14, under conditions such that the CK1 8 protein fragment present in the sample specifically binds to the first antibody and the second antibody, wherein one of the antibodies is bound to a solid support and the other antibody is bound to a detection moiety capable of producing a signal; optionally removing any unb
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: September 3, 2019
    Assignee: PDL Biopharma, Inc.
    Inventors: Jeffrey Allan Miller, Eddie Phillip Jeffries
  • Patent number: 10309973
    Abstract: The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins. The surrogate compounds of the invention typically comprise antigenic epitopes (one of which carries a post-translational modification) that are tethered by a flexible and hydrophilic linker. The resulting compound behaves like a surrogate of the post-translationally modified protein because it preserves the character of the included antigens and allows recognition by specific antibodies targeting the individual antigens.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: June 4, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: Michael Chorev, Jose A. Halperin
  • Patent number: 10261094
    Abstract: A immunogenicity assay for detecting the presence of neutralizing antibodies to a biotherapeutic protein wherein the biotherapeutic protein has been administered to a patient in need, comprising the steps of (a) obtaining a sample from the patient; (b) incubating the sample in the presence of a capture reagent; and (c) adding a detecting reagent, wherein a decreased signal relative to a control sample indicates the presence of a neutralizing antibody to the biotherapeutic agent.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: April 16, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Manoj Rajadhyaksha, Michael Partridge, Albert Torri
  • Patent number: 10234455
    Abstract: Compositions and methods for diagnosing an increased risk of NPSLE are provided.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: March 19, 2019
    Assignee: The Research Foundation for State University of New York
    Inventors: Henri Tiedge, Anna Iacoangeli
  • Patent number: 10202584
    Abstract: A bioluminescent protein is provided that includes a substituted luciferase polypeptide having amino acid substitutions at positions 21 and 166, and with one or more additional amino acid substitutions at positions 3, 16, 20, 29, 30, 71, 87, 114, and 144, compared to the parent polypeptide. Also provided is a luciferin that has a selenium-containing group at position C8 of an imidazopyrazine backbone, and methods of making the luciferin. In addition, nucleic acids encoding the bioluminescent protein, cells expressing the bioluminescent protein, and reactions between the bioluminescent protein and luciferin substrates are also provided. Fusions between the substituted luciferase polypeptide and a fluorescent protein are also provided for bioluminescence resonance energy transfer based reporters.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: February 12, 2019
    Assignee: The Regents of the University of California
    Inventors: Huiwang Ai, Hsien-Wei Yeh
  • Patent number: 10191056
    Abstract: The present invention relates to a plurality of antigens that together form a panel of immunoreactive molecules suitable for identifying candidates for prostate cancer examination. Methods for identifying antibodies indicative of a pre-malignant or malignant prostate are disclosed. Further disclosed are kits that can be used to practice the above methods.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: January 29, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Douglas G. McNeel, Brett B. Maricque
  • Patent number: 10138508
    Abstract: The present invention provides a method for measuring a modified nucleobase that increases detection sensitivity for the modified nucleobase in a target nucleic acid. Specifically, the present invention provides a method for measuring a modified nucleobase including: (1) incubating a nucleic acid sample, a capture probe, and a guide probe in a solution; and (2) measuring the modified nucleobase using an antibody against the modified nucleobase in the solution obtained at (1). The present invention also provides a kit for measuring a modified nucleobase including: (I) a guide probe; and (II) a capture probe and/or an antibody against the modified nucleobase.
    Type: Grant
    Filed: January 19, 2015
    Date of Patent: November 27, 2018
    Assignee: FUJIREBIO INC.
    Inventors: Tatsuki Matsuno, Mariko Horiike
  • Patent number: 10138268
    Abstract: The invention relates to a method for enzymatically synthesizing an (oligo)peptide, comprising coupling (a) an (oligo)peptide C-terminal ester or thioester and (b) an (oligo)peptide nucleophile having an N-terminally unprotected amine, wherein the coupling is carried out in a fluid comprising water, and wherein the coupling is catalyzed by a subtilisin BPN? variant or a homo-log thereof, which comprises the following mutations compared to subtilisin BPN? represented by SEQUENCE ID NO: 2 or a homolog sequence thereof: a deletion of the amino acids corresponding to positions 75-83; a mutation at the amino acid position corresponding to S221, the mutation being S221C or S221 selenocysteine; preferably a mutation at the amino acid position corresponding to P225 wherein the amino acid positions are defined according to the sequence of subtilisin BPN? represented by SEQUENCE ID NO: 2. Further, the invention relates to an enzyme suitable for use as a catalyst in a method of the invention.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: November 27, 2018
    Assignee: ENZYPEP B.V.
    Inventors: Peter Jan Leonard Mario Quaedflieg, Timo Nuijens, Jan Metske Van Der Laan, Dirk Barend Janssen, Ana Toplak, Bian Wu
  • Patent number: 9920136
    Abstract: Methods, compositions and kits are disclosed directed at posaconazole fragments, immunogens, signal generating moieties, antibodies that bind posaconazole and immunoassays for detection of posaconazole.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: March 20, 2018
    Assignee: ARK Diagnostics, Inc.
    Inventors: Johnny Valdez, Soon J. Oh, Byung Sook Moon
  • Patent number: 9863953
    Abstract: The present invention relates to a method for determining prognosis of cancer in a subject, which comprises the step of detecting phosphorylation of a tyrosine residue at position 2681 of TRIO in a sample obtained from the subject.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: January 9, 2018
    Assignee: KYOTO UNIVERSITY
    Inventors: Makoto Taketo, Masahiro Sonoshita, Yoshiharu Sakai, Kenji Kawada, Yoshiro Itatani
  • Patent number: 9678071
    Abstract: This document provides methods and materials related to identifying mammals having a LTBI. For example, methods and materials for using ELISpot assays to identify mammals (e.g., humans) having a LTBI are provided.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: June 13, 2017
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Patricio Escalante, Keith L. Knutson, Tobias Peikert
  • Patent number: 9630985
    Abstract: The invention provides binding agents and assays for insulin signal peptide. The agents and assays are useful in methods for predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: April 25, 2017
    Assignee: Otago Innovation Limited
    Inventors: Christopher Joseph Pemberton, Arthur Mark Richards, Michael Gary Nicholls, Timothy Grant Yandle
  • Patent number: 9588110
    Abstract: The disclosure provides methods for detecting the concurrent presence of at least two targets within a biological sample. The method includes contacting said biological sample with a first binding agent, said first binding agent operably linked to a first sortase molecule, wherein said first binding agent specifically binds to a first target; contacting said biological sample with a second binding agent, said second binding agent operably linked to a first sortase recognition sequence peptide, wherein said second binding agent specifically binds to a second target; adding a sortase substrate under conditions where a first sortase-mediated ligation of the sortase substrate to the first sortase recognition sequence will produce a ligation product, and detecting the ligation product, wherein detection of said ligation product indicates the concurrent presence of the first target and the second target in the biological sample. Also disclosed are kits comprising reagents for performing the methods as claimed.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: March 7, 2017
    Assignee: CELL SIGNALING TECHNOLOGY, INC.
    Inventors: Khanh Duc Huynh, Wan Cheung Cheung, Roberto Polakiewicz
  • Patent number: 9540675
    Abstract: An apparatus includes a housing and an actuator. The housing, which defines a reagent volume that can receive a reagent container, can be removably coupled to a reaction chamber. The housing includes a puncturer that defines a transfer pathway in fluid communication with the reagent volume. A delivery portion of the housing defines a delivery pathway between the transfer pathway and the reaction chamber when the housing is coupled to the reaction chamber. The actuator has a plunger portion disposed within the reagent volume. An engagement portion of the actuator can be manipulated to move the plunger portion within the reagent volume to deform the reagent container. The puncturer can pierce a frangible portion of the reagent container to convey a reagent from the reagent container into the reaction chamber via the transfer pathway and/or the delivery pathway.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: January 10, 2017
    Assignee: GeneWeave Biosciences, Inc.
    Inventors: Nikol De Forest, Werner Frei, Diego Rey, Shaunak Roy, Soni Shukla, Ryan C. Griswold, Kenneth G. Olson, Bruce J. Richardson, Victor H. Yee
  • Patent number: 9370588
    Abstract: This disclosure relates to luciferin amides of formula (I) shown below: Each variable in formula (I) is defined in the specification. These compounds can be used to detect fatty acid amide hydrolase activities in vitro, in live cells, or in vivo.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 21, 2016
    Assignee: University of Massachusetts
    Inventor: Stephen C. Miller
  • Publication number: 20150147326
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Application
    Filed: September 30, 2014
    Publication date: May 28, 2015
    Applicants: Daiichi Sankyo Company, Limited, U3 Pharma GmbH, Kinki University
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
  • Publication number: 20150147764
    Abstract: In a first aspect, there is provided an isolated polypeptide substrate for a disintegrin-like and metallopeptidase with thrombospondin type-1 motif, 13 (ADAMTS13) that is from 45 to 70 amino acids in length and has an amino acid sequence that is substantially similar to part of the von Willebrand factor A2 domain sequence set forth in SEQ ID NO:2, with one or more of the following modifications: (i) the amino acid corresponding to position 1599 of SEQ ID NO: 2 is mutated from Q to K; (ii) the amino acid corresponding to position 1610 of SEQ ID NO: 2 is mutated from N to C; and (iii) the amino acids corresponding to Q1624 to R1641 of SEQ ID NO: 2 are deleted.
    Type: Application
    Filed: November 9, 2012
    Publication date: May 28, 2015
    Inventors: Gian Paolo Visentin, Suzette Chance, Elizabeth Wuitschick
  • Publication number: 20150148261
    Abstract: Systems and methods for detecting and/or identifying target cells (e.g., bacteria) using engineered transduction particles are described herein. In some embodiments, a method includes mixing a quantity of transduction particles within a sample. The transduction particles are associated with a target cell. The transduction particles are non-replicative, and are engineered to include a nucleic acid molecule formulated to cause the target cell to produce a series of reporter molecules. The sample and the transduction particles are maintained to express the series of the reporter molecules when target cell is present in the sample. A signal associated with a quantity of the reporter molecules is received. In some embodiments, a magnitude of the signal is independent from a quantity of the transduction particle above a predetermined quantity.
    Type: Application
    Filed: February 2, 2015
    Publication date: May 28, 2015
    Applicant: GENEWEAVE BIOSCIENCES, INC.
    Inventors: Werner FREI, Diego Ariel REY, Shaunak ROY, Ryan C. GRISWOLD, Kenneth G. OLSON, Bruce J. RICHARDSON, Rick V. STELLMACHER
  • Publication number: 20150132778
    Abstract: Provided herein are methods for diagnosing heparin-induced thrombocytopenia (HIT) in a subject. The methods comprise (a) contacting a PF4-heparin complex with a biological sample from the subject; (b) contacting the composition of part (a) with an HIT-like antibody; and (c) measuring the amount of bound HIT-like antibody. In one embodiment, a significant decrease in the amount of bound HIT-like antibody in the composition of part (b) as compared to a control level is indicative of a diagnosis of HIT in the subject. Also provided are assay kits for performing the methods of the invention.
    Type: Application
    Filed: April 30, 2013
    Publication date: May 14, 2015
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Douglas B. Cines, Adam Cuker, Bruce Sachais
  • Publication number: 20150104455
    Abstract: Compositions and methods for treating and diagnosing acute myocardial infarction are described. The invention also provides a method of treating an individual to prevent or inhibit damage to myocardial tissue from an acute myocardial infarction comprising administering to the individual an antibody to BMP-1-3, or an antibody to BMP-1-4, or a combination of an antibody BMP-1-3 and an antibody to BMP-1-4 prior to AMI.
    Type: Application
    Filed: April 25, 2013
    Publication date: April 16, 2015
    Inventors: Slobodan Vukicevic, Lovorka Grgurevic, Ivo Dumic-Cule
  • Patent number: 9005911
    Abstract: A system and method for identifying a botulinum neurotoxin inhibitor employing a botulinum neurotoxin substrate complex having a peptide substrate, preferably SNAP-25, a reporter domain on one side of said peptide substrate and an immobilization domain on the opposite side of said peptide substrate. The botulinum neurotoxin inhibitor is identified by its ability to decrease the relative amount of cleaved complex, detected through measuring a decrease in complex bound to a solid support. The method of the present invention also utilizes novel cells that express a botulinum neurotoxin substrate complex. Also provided are novel stable cell lines that express the botulinum toxin substrate complex and viral vectors capable of efficiently expressing an active light chain of the BoNT within mammalian cells.
    Type: Grant
    Filed: January 7, 2012
    Date of Patent: April 14, 2015
    Assignee: Synaptic Research, LLC
    Inventors: Randall L. Kincaid, George Oyler, Yien Che Tsai, Paul S. Fishman
  • Patent number: 8993253
    Abstract: A polypeptide comprising a chromogenic amino acid. The chromogenic amino acid is flanked by at least one amino acid to the N and C termini thereof. The amine group of the chromogenic amino acid has a pKa of less than 5. The chromogenic amino acid is capable of reacting with a conjugated aldehyde. The polypeptide comprises a target sequence for a target protease which is capable of cleaving the peptide bond comprising the amino group of the chromogenic amino acid.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: March 31, 2015
    Assignee: Mologic Ltd
    Inventor: James Alexander Schouten
  • Publication number: 20150056190
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Priti Hegde, Maike Schmidt, Ru-Fang Yeh
  • Patent number: 8962266
    Abstract: The present invention provides compounds and methods for assaying activities of enzymes such as histone deacetylases and histone acetyltransferases. In some embodiments, the methods may be performed in one step. The compounds described herein features peptide-based compounds having at least one blocked lysine or arginine residue which are coupled to reporter moieties. The methods described herein involve reacting a compound described herein with an enzyme, such as a histone deacetylase enzyme or a histone acetyltransferase enzyme, and an endopeptidase that recognizes basic amino acids to release the reporter moiety which may be subsequently detected.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: February 24, 2015
    Assignee: Promega Corporation
    Inventors: Thomas Kirkland, Andrew L. Niles, Martha O'Brien, Carolyn Woodroofe Hitko
  • Patent number: 8956825
    Abstract: Provided herein are conjugate molecules containing a substrate for a nucleoside transport pathway linked to an active agent, wherein the conjugate can be transported into a cell or into the nucleus of a cell via a cellular nucleoside transport pathway. Further provided are methods of delivering a conjugate molecule to a target cell expressing a nucleoside transport pathway, wherein the conjugate contains a substrate for the nucleoside transport pathway linked to an active agent. Also provided are methods for screening for conjugates that are transported by nucleoside transport pathways. Further provided are methods of treating a patient having a disease or disorder affecting tissues expressing nucleoside transport pathways, in which a conjugate containing an agent effective in treating the disorder is administered to the patient. Also provided are methods of treating a patient having an autoimmune disorder involving administering to the patient a compound that inhibits a nucleoside transport pathway.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: February 17, 2015
    Assignee: The United States of America as represented by the Department of Veterans Affairs
    Inventor: Richard H. Weisbart
  • Publication number: 20150037341
    Abstract: The present invention relates to a method of treating or preventing transthyretin amyloidosis, pharmaceutical composition for use in said treatment or prevention, as well as to a diagnostic method and a kit.
    Type: Application
    Filed: February 21, 2012
    Publication date: February 5, 2015
    Applicant: Plysackaridforskning i Uppsala AB
    Inventors: Ulf Lindahl, Jin-ping Li, Fredrik Noborn
  • Publication number: 20150024415
    Abstract: A general methodology for highly sensitive and selective sensors that can achieve portable, low-cost and quantitative detection of a broad range of targets using only a personal glucose meter (PGM) is disclosed. The method and sensors take advantage of the ability of alkaline phosphatase (ALP) to convert glucose-1-phosphate to glucose, and the ability of PGMs to detect the generated glucose. The disclosed sensors can be part of a lateral flow device. Methods of using such sensors for detecting target agents, for example to diagnose disease, are also provided.
    Type: Application
    Filed: February 19, 2013
    Publication date: January 22, 2015
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Yi Lu, Yu Xiang
  • Patent number: 8921620
    Abstract: A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: December 30, 2014
    Assignee: Promega Corporation
    Inventors: Keith V. Wood, Dieter Klaubert, Georgyi V. Los, Robert F. Bulleit, Mark McDougall, Chad Zimprich
  • Publication number: 20140377783
    Abstract: A novel type of dye systems comprises a selection of 10H-indolo[1,2-a]indole compounds (henceforth abbreviated as IO compounds) and (5H,7H)-indolo[1,2-a]quinoline compounds (henceforth abbreviated as IQ compounds) showing a solvatochromic effect and exhibiting strong fluorescence in a variety of materials such as polypropylene, polyethylene, oils, various solvents, emulsions. Also disclosed are various methods how the IO/IQ compounds can be administered, especially how they can be produced and administered in situ from a precursor, responding to external stimuli such as enzyme activity, temperature and so forth. The response of a precursor to external stimuli can also be used to determine the presence or absence of such stimuli.
    Type: Application
    Filed: November 4, 2011
    Publication date: December 25, 2014
    Inventors: Lukas Wick, Urs Spitz, Christophe Weymuth, Günter Schabert, Thomas Mayer, Alexander Bayer
  • Patent number: 8906637
    Abstract: The present invention provides method and compositions for detecting target molecules present on cells and tissues. In particular, the methods involve adding primary antibodies such as scFv-targeted lactamase that are directed against a target of interest (e.g., cancer markers) to a tissue sample, followed by adding a lactam-containing compound and finally a lactamase reporter system. In some preferred embodiments, the lactamase reporters are fluorescent reporters that bind to the test tissue. In some particularly preferred embodiments, the test tissue contains at least once cancer cell and/or at least one cancer-associated marker.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: December 9, 2014
    Assignee: Danisco US Inc.
    Inventor: Steven W. Sherwood
  • Publication number: 20140356885
    Abstract: Methods and reagents are disclosed for preparing a support for reaction of the support with an assay molecule. In the method the support is treated with a detergent at a concentration of about 0.01% to about 5% (by weight) at a temperature of about 4° C. to about 50° C. for a period of about 1 hour to about 24 hours and subsequently the support is washed. The support is contacted with the assay molecule under conditions for covalently binding the assay molecule to the support to form a conjugate of the support and the assay molecule.
    Type: Application
    Filed: May 30, 2013
    Publication date: December 4, 2014
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Rafael Bartz, Pratap Singh, Liping Geng, Gladys Privon
  • Patent number: 8900879
    Abstract: Embodiments of the present disclosure set forth a sensor for detecting a target of interest. One example sensor may comprise an apparatus for binding the target of interest and a draining unit for draining fluid from the apparatus. The apparatus may comprise a substrate, a material disposed on the substrate, and a probe disposed on the material and configured to bind to the target of interest. The probe is configured on the material to scatter light emitted from a light source when the target of interest is bound to the probe.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: December 2, 2014
    Assignee: National Taiwan University
    Inventors: Shiming Lin, Si-Chen Lee, Luan-Yin Chang
  • Patent number: 8895787
    Abstract: A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: November 25, 2014
    Assignee: Promega Corporation
    Inventors: Keith V. Wood, Georgyi V. Los, Robert F. Bulleit, Dieter Klaubert, Mark McDougall, Chad Zimprich
  • Patent number: 8889345
    Abstract: Provided is a detection method of NADP(H) from the change of a fluorescence intensity by a reaction between metagenome-derived blue fluorescent protein (mBFP) and NADPH. More particularly, the present invention relates to methods for detecting NADP(H) using mBFP or his-mBFP, or methods for detecting NADP(H) for measuring an activity of NADP(H) dependent dehydrogenase or oxidoreductase.
    Type: Grant
    Filed: December 24, 2012
    Date of Patent: November 18, 2014
    Assignee: Industry Foundation of Chonnam National University
    Inventors: Geun Joong Kim, Sung Hwan You
  • Publication number: 20140327158
    Abstract: The present invention provides a screen which exploits mechanism-based activity probes that specifically and covalently modify the active site cysteine thiol residue of E3 Ub ligases including, but not limited to the HECT and RBR family. The activity probes are used to screen for activators and inhibitors of E3 Ub ligases, and to interrogate the functional state of E3 Ub ligases in human disease.
    Type: Application
    Filed: May 2, 2014
    Publication date: November 6, 2014
    Applicant: E3X BIO
    Inventors: Brigit Riley, Jennifer Johnston, David Morgans
  • Publication number: 20140315741
    Abstract: This document relates to methods and materials involved in modulating deubiquitinases (e.g., USP10 polypeptides) and/or ubiquitinated polypeptides (e.g., tumor suppressor polypeptides or mutant versions of tumor suppressor polypeptides). For example, methods and materials for increasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for decreasing deubiquitinase (e.g., a USP10 polypeptide) expression or activity, methods and materials for stabilizing tumor suppressor polypeptides (e.g., wild-type p53 polypeptides), methods and materials for de-stabilizing mutant versions of tumor suppressor polypeptides (e.g., mutant p53 polypeptides), and methods and materials for reducing cancer cell proliferation, increasing cancer cell apoptosis, and/or treating cancer (e.g., cancers having reduced levels of wild-type p53 polypeptides or cancers having increased levels of mutant p53 polypeptides) are provided.
    Type: Application
    Filed: July 1, 2014
    Publication date: October 23, 2014
    Inventors: Zhenkun Lou, Jian Yuan
  • Patent number: 8865479
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: October 21, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Publication number: 20140302531
    Abstract: Disclosed herein are methods and kits which are useful for detecting presence of an enzyme in a test sample based upon the intrinsic enzymatic activity of such test sample. The present invention provides the ability to evaluate cell culture conditions and optimize the desired glycoform content of recombinantly prepared enzymes.
    Type: Application
    Filed: June 9, 2014
    Publication date: October 9, 2014
    Applicant: Shire Human Genetic Therapies, Inc.
    Inventor: Daniel S. Roseman
  • Publication number: 20140287439
    Abstract: Provided is a method for manufacturing a multiple-diagnosis membrane sensor provided with multiple channels by using screen printing, and more specifically, to a method for manufacturing a membrane sensor capable of performing multiple-diagnosis by screen-printing hydrophobic ink on a membrane to form multiple channels. The membrane sensor according to the present invention may enable mass-production of sensors and secure reliability of detection by forming the plurality of channels on the membrane by a simple method.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 25, 2014
    Inventors: Min-Gon Kim, Hyou-Arm Joung, Jun-Hyoung Ahn, Ho-Jun Suk
  • Publication number: 20140273021
    Abstract: The disclosure relates to methods for measuring levels of 25(OH)vitamin D (25OHD) in a mammalian fluid sample. The disclosure further relates to kits for measuring levels of 25(OH)vitamin D (25OHD) in a mammalian fluid.
    Type: Application
    Filed: March 14, 2013
    Publication date: September 18, 2014
    Inventors: JOHN F. ZIELINSKI, RORY J. OLSON, MICHAEL C. MULLENIX
  • Patent number: 8835188
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: September 16, 2014
    Assignee: Presidents and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Patent number: 8835187
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: September 16, 2014
    Assignee: Presidents and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Patent number: 8835125
    Abstract: Disclosed are compositions and methods for the labeling of two or more targets with different labels. Specifically, disclosed are compositions for biotin and the protection of biotin within multilabel assays which employ the biotin-biotin binding protein binding relationship for each distinct label in relation to targets such as nucleic acids, polypeptides, antibodies or cells. These multilabel assays are enabled through the use of biotin with desthiobiotin, orthogonal protecting schemes for biotin, or a combination of the approaches.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: September 16, 2014
    Assignee: Affymetrix, Inc.
    Inventors: Robert G. Kuimelis, Glenn H. McGall, Stephen P. A. Fodor
  • Publication number: 20140234870
    Abstract: The present invention relates to a cell-based assay for the screening and the identification of inhibitors of NIK protein. The method according to the present invention allows the identification of compounds that inhibit NIK activity related to the phosphorylation of IKK1. The assay combines the use of transfected Human Embryonic Kidney (HEK) cells with a non-radioactive, homogeneous proximity assay using an “acceptor” bead and a “donor” bead.
    Type: Application
    Filed: July 26, 2012
    Publication date: August 21, 2014
    Applicant: Merck Patent GmbH
    Inventors: Rob Hooft Van Huijsduijnen, Sheraz Gul
  • Publication number: 20140206020
    Abstract: Methods, compositions and kits are disclosed directed at voriconazole derivatives, immunogens, signal generating moieties, antibodies that bind voriconazole and immunoassays for detection of voriconazole.
    Type: Application
    Filed: January 17, 2014
    Publication date: July 24, 2014
    Inventors: Johnny Valdez, SOON J. OH, BYUNG SOOK MOON
  • Patent number: 8785148
    Abstract: Described herein is a method and a device for expediting delivery of an agent to a damaged bacterial cell. In one embodiment, the methods and devices are useful for screening candidate antibiotics. In another embodiment, the methods and devices described herein are used to determine susceptibility of bacteria to an antibiotic. The methods also provide a method for determining an appropriate antibiotic to treat an individual having a bacterial infection.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: July 22, 2014
    Assignees: Fraunhofer, USA, Inc., Trustees of Boston University
    Inventors: Alexis Sauer-Budge, Andre Sharon, Maxim Kalashnikov, Holger Wirz
  • Patent number: 8779221
    Abstract: A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate and has at least two amino acid substitutions relative to the wild-type hydrolase. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: July 15, 2014
    Assignee: Promega Corporation
    Inventors: Aldis Darzins, Lance Encell, Tonny Johnson, Dieter Klaubert, Georgyi V. Los, Mark McDougall, Keith V. Wood, Monika G. Wood, Chad Zimprich
  • Patent number: 8772049
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: July 8, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Patent number: 8759018
    Abstract: A method for determining an appropriate treatment option for a patient who has been diagnosed with disseminated intravascular coagulation (DIC) but who may have thrombotic thrombocytopenic purpura (TTP), by analyzing the amount and/or enzyme activity of a von Willebrand factor (vWF)-cleaving protease (ADAMTS13) and the amount of vWF in a patient that has been diagnosed with DIC is disclosed. Using the method of the present invention, a differential diagnosis of patients with thrombotic thrombocytopenic purpura (TTP) can be made from among patients diagnosed with DIC, which could not previously be distinguished on the basis of only clinical findings or known markers. Also disclosed is a kit for determining an appropriate treatment option, the kit comprising an antibody or a fragment thereof which specifically binds to ADAMTS13.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: June 24, 2014
    Assignees: Mitsubishi Chemical Medience Corporation, Juridical Foundation the Chemo-Sero-Therapeutic Research Institute
    Inventors: Tomoko Ono, Shinichiro Watanabe, Fumio Furusaki, Ko Igami
  • Patent number: 8758993
    Abstract: Methods, processes, systems, and apparatuses are disclosed for predicting anti-androgen therapy response in the treatment of androgenetic alopecia based on a fluorometric assay and proteomics.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: June 24, 2014
    Assignee: Global Life Science Partners Limited
    Inventors: Andy Ofer Goren, John McCoy